Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $33.5700 (0.9%) ($33.5700 - $33.5700) on Fri. Oct. 1, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.63% (three month average) | RSI | 72 | Latest Price | $33.5700(0.9%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.8% a day on average for past five trading days. | Weekly Trend | TGTX advances 5.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(69%) ARKG(65%) ARKK(60%) IBB(60%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -2.315% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-18%) UNG(-4%) TLT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.315% (StdDev 4.63%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $33.6(-0.09%) | 10 Day Moving Average | $32.55(3.13%) | 20 Day Moving Average | $31.39(6.94%) | To recent high | -17% | To recent low | 54.8% | Market Cap | $4.252b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |